Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine

Elizabeth Miller; Nicholas J. Andrews; Pauline A. Waight; Mary P.E. Slack; Robert C. George

doi:10.1016/j.vaccine.2011.09.112

Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine

Elizabeth Miller^*, Nicholas J. Andrews, Pauline A. Waight, Mary P.E. Slack, Robert C. George

^*Corresponding author for this work

Immunisation Hepatitis and Blood Safety

Research output: Contribution to journal › Article › peer-review

178 Citations (Scopus)

Abstract

Efficacy of the new serotypes in the 13-valent pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease (IPD) was based on a putative correlate of protection. In England and Wales, PCV13 replaced PCV7 in the 2, 4, and 13 month schedule in April 2010. Using non-vaccine type IPD cases as controls, we estimated vaccine effectiveness (VE) for the new serotypes. Among 166 IPD cases in PCV13 eligible children reported by July 2011 with known serotype and vaccination status, VE for 2 doses under a year was 78% (95% confidence interval -18% to 96%) and 77% (38-91%) for one dose over a year. VE for 7F and 19A was 76% (21-93%) and 70% (10-90%) respectively for ≥one dose. VE for serotypes 1 and 3 was 62% and 66% respectively although confidence intervals spanned zero. IPD due to PCV13-only serotypes halved in children under 2 years in the study period.

Original language	English
Pages (from-to)	9127-9131
Number of pages	5
Journal	Vaccine
Volume	29
Issue number	49
DOIs	https://doi.org/10.1016/j.vaccine.2011.09.112
Publication status	Published - 15 Nov 2011

Bibliographical note

Funding Information:
Contributors: MS and RG were responsible for serotyping of isolates, PW oversaw data collection and data management, NA conducted the statistical analysis and EM wrote the paper. All authors contributed to the study design and read and approved the final version of the paper. Conflict of interest statement: RG and MS have received assistance to attend scientific meetings from Wyeth (Pfizer) and GlaxoSmithKline, and their laboratory has received research funding from Wyeth (Pfizer) and GSK. EM, PW, and NA have no conflicts of interest. Funding: The study was funded by the Health Protection Agency . The Health Protection Agency has approval under PIAG Section 60 of the Health and Social Act 2001 (which has subsumed into the National Information Governance Board for Health and Social Care with Section 60 – now Section 251 of the NHS Act 2006) to process confidential information from patients for the purposes of monitoring the efficacy and safety of vaccination programmes.

Keywords

13-Valent vaccine
Invasive pneumococcal disease
Pneumococcal conjugate vaccine
Vaccine effectiveness

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2011.09.112

Cite this

@article{c9803c6c5de64d38827072681b2f3992,

title = "Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine",

abstract = "Efficacy of the new serotypes in the 13-valent pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease (IPD) was based on a putative correlate of protection. In England and Wales, PCV13 replaced PCV7 in the 2, 4, and 13 month schedule in April 2010. Using non-vaccine type IPD cases as controls, we estimated vaccine effectiveness (VE) for the new serotypes. Among 166 IPD cases in PCV13 eligible children reported by July 2011 with known serotype and vaccination status, VE for 2 doses under a year was 78% (95% confidence interval -18% to 96%) and 77% (38-91%) for one dose over a year. VE for 7F and 19A was 76% (21-93%) and 70% (10-90%) respectively for ≥one dose. VE for serotypes 1 and 3 was 62% and 66% respectively although confidence intervals spanned zero. IPD due to PCV13-only serotypes halved in children under 2 years in the study period.",

keywords = "13-Valent vaccine, Invasive pneumococcal disease, Pneumococcal conjugate vaccine, Vaccine effectiveness",

author = "Elizabeth Miller and Andrews, {Nicholas J.} and Waight, {Pauline A.} and Slack, {Mary P.E.} and George, {Robert C.}",

note = "Funding Information: Contributors: MS and RG were responsible for serotyping of isolates, PW oversaw data collection and data management, NA conducted the statistical analysis and EM wrote the paper. All authors contributed to the study design and read and approved the final version of the paper. Conflict of interest statement: RG and MS have received assistance to attend scientific meetings from Wyeth (Pfizer) and GlaxoSmithKline, and their laboratory has received research funding from Wyeth (Pfizer) and GSK. EM, PW, and NA have no conflicts of interest. Funding: The study was funded by the Health Protection Agency . The Health Protection Agency has approval under PIAG Section 60 of the Health and Social Act 2001 (which has subsumed into the National Information Governance Board for Health and Social Care with Section 60 – now Section 251 of the NHS Act 2006) to process confidential information from patients for the purposes of monitoring the efficacy and safety of vaccination programmes. ",

year = "2011",

month = nov,

day = "15",

doi = "10.1016/j.vaccine.2011.09.112",

language = "English",

volume = "29",

pages = "9127--9131",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "49",

}

TY - JOUR

T1 - Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine

AU - Miller, Elizabeth

AU - Andrews, Nicholas J.

AU - Waight, Pauline A.

AU - Slack, Mary P.E.

AU - George, Robert C.

N1 - Funding Information: Contributors: MS and RG were responsible for serotyping of isolates, PW oversaw data collection and data management, NA conducted the statistical analysis and EM wrote the paper. All authors contributed to the study design and read and approved the final version of the paper. Conflict of interest statement: RG and MS have received assistance to attend scientific meetings from Wyeth (Pfizer) and GlaxoSmithKline, and their laboratory has received research funding from Wyeth (Pfizer) and GSK. EM, PW, and NA have no conflicts of interest. Funding: The study was funded by the Health Protection Agency . The Health Protection Agency has approval under PIAG Section 60 of the Health and Social Act 2001 (which has subsumed into the National Information Governance Board for Health and Social Care with Section 60 – now Section 251 of the NHS Act 2006) to process confidential information from patients for the purposes of monitoring the efficacy and safety of vaccination programmes.

PY - 2011/11/15

Y1 - 2011/11/15

N2 - Efficacy of the new serotypes in the 13-valent pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease (IPD) was based on a putative correlate of protection. In England and Wales, PCV13 replaced PCV7 in the 2, 4, and 13 month schedule in April 2010. Using non-vaccine type IPD cases as controls, we estimated vaccine effectiveness (VE) for the new serotypes. Among 166 IPD cases in PCV13 eligible children reported by July 2011 with known serotype and vaccination status, VE for 2 doses under a year was 78% (95% confidence interval -18% to 96%) and 77% (38-91%) for one dose over a year. VE for 7F and 19A was 76% (21-93%) and 70% (10-90%) respectively for ≥one dose. VE for serotypes 1 and 3 was 62% and 66% respectively although confidence intervals spanned zero. IPD due to PCV13-only serotypes halved in children under 2 years in the study period.

AB - Efficacy of the new serotypes in the 13-valent pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease (IPD) was based on a putative correlate of protection. In England and Wales, PCV13 replaced PCV7 in the 2, 4, and 13 month schedule in April 2010. Using non-vaccine type IPD cases as controls, we estimated vaccine effectiveness (VE) for the new serotypes. Among 166 IPD cases in PCV13 eligible children reported by July 2011 with known serotype and vaccination status, VE for 2 doses under a year was 78% (95% confidence interval -18% to 96%) and 77% (38-91%) for one dose over a year. VE for 7F and 19A was 76% (21-93%) and 70% (10-90%) respectively for ≥one dose. VE for serotypes 1 and 3 was 62% and 66% respectively although confidence intervals spanned zero. IPD due to PCV13-only serotypes halved in children under 2 years in the study period.

KW - 13-Valent vaccine

KW - Invasive pneumococcal disease

KW - Pneumococcal conjugate vaccine

KW - Vaccine effectiveness

UR - http://www.scopus.com/inward/record.url?scp=82555187917&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.09.112

DO - 10.1016/j.vaccine.2011.09.112

M3 - Article

C2 - 21983361

AN - SCOPUS:82555187917

SN - 0264-410X

VL - 29

SP - 9127

EP - 9131

JO - Vaccine

JF - Vaccine

IS - 49

ER -

Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this